Studies have indicated that breast cancer patients with heightened levels of LOX expression tend to have notably reduced distant metastasis-free survival (DMFS) 20, highlighting the potential involvement of LOX family proteins in the complex mechanisms driving breast cancer progression and pathogenesis (Table 2). Here, LOX is linked to breast carcinoma.